1011464-42-8

Basic information

• Product Name: ethyl 2-tert-butyl-4-chloropyrimidine-5-carboxylate
• Synonyms: ethyl 2-tert-butyl-4-chloropyrimidine-5-carboxylate
• CAS NO: 1011464-42-8
• Molecular Formula: C₁₁H₁₅ClN₂O₂
• Molecular Weight: 242.702
• Mol File: 1011464-42-8.mol
• Article Data: 6

Chemical Properties

• Appearance: /
• CAS DataBase Reference: ethyl 2-tert-butyl-4-chloropyrimidine-5-carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: ethyl 2-tert-butyl-4-chloropyrimidine-5-carboxylate(1011464-42-8)
• EPA Substance Registry System: ethyl 2-tert-butyl-4-chloropyrimidine-5-carboxylate(1011464-42-8)

Safety Data

• Hazardous Substances Data: 1011464-42-8(Hazardous Substances Data)

Upstream product

• 59950-56-0 pivalimidamide 
• 18202-73-8 pivalamidine hydrochloride 
• 827014-34-6 ethyl 2-tert-butyl-6-oxo-1,6-dihydropyrimidine-5-carboxylate 
• 87-13-8 diethyl 2-ethoxymethylenemalonate 
• 827014-34-6 2-(tert-butyl)-4-hydroxypyrimidine-5-carboxylic acid ethyl ester 

Relevant articles and documents

MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR

The present invention features a compound of formula I: or a pharmaceutically acceptable salt thereof, where R1, R2, R3, W, X, Y, Z, n, o, p, and q are defined herein, for the treatment of CFTR mediated diseases, such as cystic fibrosis. The present invention also features pharmaceutical compositions, method of treating, and kits thereof.

Structure-based design of a new series of N-(piperidin-3-yl)pyrimidine-5-carboxamides as renin inhibitors

The action of the aspartyl protease renin is the rate-limiting initial step of the renin-angiotensin-aldosterone system. Therefore, renin is a particularly promising target for blood pressure as well as onset and progression of cardiovascular and renal diseases. New pyrimidine derivatives 5–14 were designed in an attempt to enhance the renin inhibitory activity of compound 3 identified by our previous fragment-based drug design approach. Introduction of a basic amine essential for interaction with the two aspartic acids in the catalytic site and optimization of the S1/S3 binding elements including an induced-fit structural change of Leu114 (‘Leu-in’ to ‘Leu-out’) by a rational structure-based drug design approach led to the discovery of N-(piperidin-3-yl)pyrimidine-5-carboxamide 14, a 65,000-fold more potent renin inhibitor than compound 3. Surprisingly, this remarkable enhancement in the inhibitory activity of compound 14 has been achieved by the overall addition of only seven heavy atoms to compound 3. Compound 14 demonstrated excellent selectivity over other aspartyl proteases and moderate oral bioavailability in rats.

KINASE INHIBITORS USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES

The present invention relates to novel kinase inhibitors and modulator compounds useful for the treatment of various diseases. More particularly, the invention is concerned with such compounds, kinase/compound adducts, methods of treating diseases, and methods of synthesis of the compounds. Preferrably, the compounds are useful for the modulation of kinase activity of Raf kinases and disease polymorphs thereof. Compounds of the present invention find utility in the treatment of mammalian cancers and especially human cancers including but not limited to malignant melanoma, colorectal cancer, ovarian cancer, papillary thyroid carcinoma, non small cell lung cancer, and mesothelioma. Compounds of the present invention also find utility in the treatment of rheumatoid arthritis and retinopathies including diabetic retinal neuropathy and macular degeneration.